News & Media

Newsroom

SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan

10.13.2020

SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

9.11.2020

SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care

7.15.2020

Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures

5.20.2020

SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia

5.20.2020

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top